Company intelligence / Profile preview

Micron

Atlanta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

Micron's needle-free measles-rubella vaccine has been shown to be safe and immunogenic in children as young as 9 months old. The company is advancing toward the world's first Phase 2 clinical trial of needle-free drug and vaccine technology in infants. First-in-human clinical trials for next-generation rotavirus vaccine (CC24) launched in June 2025 in collaboration with Emory University and CDC.

Therapeutic areas: Women's HealthInfectious Diseases
Modalities: VaccineDevice
Industry: Biotech

Partnerships

Bill & Melinda Gates FoundationCenters for Disease Control and PreventionCoalition for Epidemic Preparedness InnovationsBiomedical Advanced Research and Development AuthorityPATHUNICEFEmory UniversityZipcode Bio

Beyond the preview

Go deeper on Micron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micron.

Explore the full profile